Holen Sie sich die Stockscreener-App
0.7165
3.11%
0.0216
Schlusskurs vom Vortag:
$0.6949
Offen:
$0.6959
24-Stunden-Volumen:
389.54K
Relative Volume:
0.36
Marktkapitalisierung:
$49.41M
Einnahmen:
$3.67M
Nettoeinkommen (Verlust:
$-13.83M
KGV:
-2.5589
EPS:
-0.28
Netto-Cashflow:
$-10.79M
1W Leistung:
+1.93%
1M Leistung:
-0.61%
6M Leistung:
-30.77%
1J Leistung:
-11.86%
1-Tages-Spanne:
$0.681
$0.7165
1-Wochen-Bereich:
$0.67
$0.7342
52-Wochen-Spanne:
$0.59
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Firmenname
Icecure Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.7165 | 47.92M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Icecure Medical Ltd Aktie (ICCM) Neueste Nachrichten
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting - PR Newswire
Cryoablation: The Minimally Invasive Freezing Technology That's a Game-Changer for Treating Low-Risk, Early-Stage Breast Cancer - Future of Personal Health -
IceCure Medical (Nasdaq: ICCM) data show ProSense cuts AWE pain scores to 1 - Stock Titan
Icecure Receives Notice of Patent Allowance in China for A Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - marketscreener.com
IceCure Medical (ICCM) Secures Patent Approval in China for Cryo - GuruFocus
IceCure Medical Secures Patent in China for Cryogen Flow Control - TipRanks
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - StreetInsider
IceCure Medical secures patent in China for cryogen flow control - MSN
Why IceCure Medical Ltd stock remains on buy listsJuly 2025 Movers & Real-Time Volume Analysis Alerts - Newser
How IceCure Medical Ltd stock benefits from global expansionJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - Newser
ICCM SEC FilingsIcecure Medical Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
IceCure Medical schedules special shareholder meeting for January 2026 By Investing.com - Investing.com Canada
IceCure Medical schedules special shareholder meeting for January 2026 - Investing.com
IceCure Medical Announces Special General Meeting for Key Votes - TipRanks
Icecure Medical (ICCM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Why retail investors pile into IceCure Medical Ltd stockJuly 2025 Catalysts & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances (PR Newswire) - Aktiellt
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Nav - GuruFocus
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period (PR Newswire) - Aktiellt
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2025 Earnings Call Transcript - Insider Monkey
How IceCure Medical Ltd stock compares to market leadersJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Is IceCure Medical Ltd stock a bargain at current levels2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
IceCure Medical Reports Q3 2025 Financial Results - TipRanks
Is IceCure Medical Ltd a candidate for recovery playJuly 2025 Sentiment & Fast Gain Swing Trade Alerts - newser.com
IceCure Medical Ltd stock momentum explained2025 Year in Review & Verified Stock Trade Ideas - newser.com
Using Ichimoku Cloud for IceCure Medical Ltd technicals - newser.com
IceCure Medical’s Earnings Call Highlights Growth Potential - TipRanks
ICCM: FDA approval of ProSense drives growth prospects amid revenue decline and strong cash position - TradingView
Does IceCure Medical Ltd fit your quant trading modelJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
IceCure Medical Q3 2025 Earnings Call Transcript - MarketBeat
IceCure Medical Gains FDA Approval for ProSense® in Breast Cancer Treatment - MSN
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025 - marketscreener.com
IceCure Medical Ltd. (ICCM) Q3 FY2025 earnings call transcript - Yahoo Finance
ICCM: FDA approval for ProSense® sets stage for accelerated growth despite lower 2025 revenue - TradingView
When is the best time to exit IceCure Medical LtdTrade Analysis Report & Fast Gain Stock Trading Tips - newser.com
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - Eastern Progress
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 - Finviz
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - Finviz
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - The Malaysian Reserve
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Report Preview: What To Expect - GuruFocus
IceCure's ProSense® cryoablation system receives regulatory approval in Switzerland for indications including breast, lung, liver, and kidney cancer - MarketScreener
IceCure Medical receives Nasdaq minimum bid price notification - Medical Buyer
Why IceCure Medical Ltd stock attracts high net worth investors2025 Stock Rankings & Expert Curated Trade Ideas - newser.com
Finanzdaten der Icecure Medical Ltd-Aktie (ICCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):